Ben R. Taylor - 16 Jun 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: RXRX
Reported as of: 16 Jun 2025
Net transaction value: -$34,720
SEC form: 4
Accepted by SEC: 18 Jun 2025, 16:32:45 UTC
Prior SEC filing: 19 May 2025
Next SEC filing: 19 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Kyle Nelson, attorney-in-fact

Key filing fact

Ben R. Taylor filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 18 Jun 2025.

Key facts

This page summarizes Ben R. Taylor's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
1 reported transaction and 5 derivative rows are listed below.
Accepted by SEC: 18 Jun 2025, 16:32.

Change

Previous filing in this sequence was filed on 19 May 2025.
Current net transaction value: -$34,720.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001712276 Primary reporting owner

Taylor Ben R

Relationship: Chief Financial Officer
Address: 41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature: /s/ Kyle Nelson, attorney-in-fact
Signature date: 18 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Tax liability

Transaction value: $34,720
Shares: -7,057
Change %: -0.85%
Price: $4.92
Shares after: 823,134
Date: 16 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 70,037
Date: 16 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $7.25
Footnotes: F2

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 740,686
Date: 16 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $6.09
Footnotes: F3

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 81,154
Date: 16 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $0.1400
Footnotes: F4

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 92,748
Date: 16 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $0.0600
Footnotes: F5

RXRX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 289,837
Date: 16 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 0
Exercise price: $0.0400
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Footnote F2

The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

Footnote F3

1/48th of the shares subject to the award vests and become exercisable on January 2, 2025, and each month thereafter, subject to Mr. Taylor's continued service through each vesting date.

Footnote F4

Twenty-five percent of the shares subject to the award vest and become exercisable on July 1, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.

Footnote F5

Twenty-five percent of the shares subject to the award vest and become exercisable on April 3, 2022, and the remaining shares subject to the award vest and become exercisable in quarterly installments thereafter, subject to Mr. Taylor's continued service through each vesting date.

Footnote F6

Twenty-five percent of the shares subject to the award vest and become exercisable on November 17, 2021, and the remaining shares subject to the award vest and become exercisable in annual installments thereafter, subject to Mr. Taylor's continued service through each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .